You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Increasing size of Phase 2b clinical trial to 60 patients

    SBC: PAIN THERAPEUTICS, INC.            Topic: NIA

    Project Summary/Abstract PTI-125 is a novel small molecule Alzheimer’s disease (AD) therapeutic candidate with a novel target and mechanism of action. PTI-125 binds and reverses an altered conformation of the scaffolding protein filamin A (FLNA) to prevent Aβ42’s tight binding to and toxic signaling via the α7-nicotinic acetylcholine receptor (α7nAChR) as well as Aβ42’s aberrant activati ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  2. DRIVEN: Accelerating Medical Entrepreneurship in the Northeast

    SBC: CELDARA MEDICAL, LLC            Topic: 500

    Project Summary This project describes the formation, launch and operation of the DRIVEN Accelerator Hub, with the express goal of reducing morbidity and mortality by increasing the number of medical entrepreneurs and their level of competency. The Hub is focused on the Northeast and, in collaboration with similar Hubs, will contribute nationwide. It will, in a facile, complete, and accessible way ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  3. Development of an oral therapeutic to mimic the anti-diabetic effects of gastric bypass surgery

    SBC: BIOKIER, INC.            Topic: 200

    SUMMARY Glucose homeostasis and food intake are both regulated by gut hormones secreted from enteroendocrine L- cells in the lower gut following stimulation by nutrients. This process is impaired in diabetes but is restored with delivery of dietary nutrients such as amino acids and fatty acids to the lower gut, such as after gastric bypass surgery and during fermentation of carbohydrates in the co ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  4. New Class of Bright, Sharp, Tunable Near-Infrared Fluorophores for Flow Cytometry

    SBC: Nirvana Sciences, Inc.            Topic: NIAID

    Abstract Polychromatic flow cytometry (FC) is one of the most powerful analytical techniques routinely used by both basic research and clinical diagnostics laboratories for the immunological categorization of cells. Dyes used for FC typically exhibit broad fluorescent emission bands with full-width-at-half-maximum (fwhm) values of 50–80 nm. This limits the maximum number of dyes, and thus the nu ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Lactoferrin as an Adjuvant for Cellular Immunity

    SBC: Pharmareview Corporation            Topic: N/A

    The Specific Aims of the proposal will be modified to reflect a change in scope, according to recommendations from the review panel. Specifically, the revised scope of the project will now only include AIM I and AIM II of the proposal. There will be no change in scope to the first two aims. All experiments proposed in AIMs I and II can be accelerated to meet the two year time commitment. Regarding ...

    STTR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  6. Advanced development of a novel nanoparticle conjugate vaccine for Salmonella Paratyphi A

    SBC: KJ BIOSCIENCES LLC            Topic: NIAID

    Salmonella Paratyphi ASParatyphi Ais a major cause of life threatening enteric feverThere is no vaccine available against this pathogenIn the SBIR phase I studieswe have successfully demonstrated the technical feasibility of a novel nanoparticle conjugate vaccine candidate for SParatyphi AIt is based on O polysaccharideOPSantigen conjugated to a novel and highly advantageous nanoparticle protein c ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Preclinical Development of OCF001 for Treatment of Yeast Infections

    SBC: Sano Chemicals, Inc.            Topic: NIAID

    Project Summary Occidiofungins (A-D) are cyclic nonribosomally synthesized antifungal peptides with submicromolar fungicidal activity against a broad spectrum of fungi. Optimization of the production and isolation of occidiofungins from liquid cultures has been performed. The production and isolation of predominantly one analog, called occidiofungin B (OCF001), supports its commercial development ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Development of a New Carbohydrate-based Anticoagulant Drug

    SBC: GLYCAN THERAPEUTICS CORPORATION            Topic: NHLBI

    Low molecular weight heparins (LMWHs) are partially depolymerized natural products of heparin, which are isolated from porcine intestine. A worldwide distribution of contaminated heparin in 2007 was associated with 85 deaths in the US. This crisis revealed the vulnerability of the LMWH supply chain. LMWHs are complex mixtures, having average molecular masses of 3500-6000 Daltons, corresponding to ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Instant Kit Synthesis of 62Cu Radiopharmaceuticals

    SBC: PROPORTIONAL TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Positron Emission Tomography (PET) is a rapidly emerging non-invasive imaging technique with the exceptional ability to provide quantitative functional information. Unfortunately, this modality is currently limited to a single approved radiopharmaceutical agent, 18F-FDG, which measures tumor metabolism. The potential of PET in oncology can be advanced substa ...

    SBIR Phase II 2005 Department of Health and Human ServicesNational Institutes of Health
  10. Novel assay to monitor Tacrolimus levels at the point of care

    SBC: AFFINERGY, LLC            Topic: NIAID

    SUMMARY/ABSTRACT In 2016, over 33,000 organ transplants were performed in the United States, an increase of 20% over the past 5 years. Organ transplantation requires lifelong immunosuppression to prevent rejection of the transplant. Tacrolimus, a macrolide antibiotic, is one of the most effective immunosuppressants, with andgt;90% of solid organ transplant recipients receiving it as part of their ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government